Publications Peter Nygren

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

Tabernero, Josep; Yoshino, Takayuki; Stintzing, Sebastian; de Gramont, Aimery et al.

Part of Cancer Research Communications, p. 28-37, 2024

• DOI for A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
• Download full text (pdf) of A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Lindskog, Magnus et al.

Part of BMC Pharmacology & Toxicology, 2024

• DOI for Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
• Download full text (pdf) of Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Andersson, Claes; Ye, Jiawei; Blom, Kristin; Fryknäs, Mårten et al.

Part of Anti-Cancer Drugs, p. 92-102, 2023

• DOI for Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
• Download full text (pdf) of Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Cashin, Peter; Söderström, Maria; Blom, Kristin; Artursson, Sara et al.

Part of British Journal of Surgery, p. 1080-1083, 2023

• DOI for Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
• Download full text (pdf) of Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Jarvius, Malin et al.

Part of BMC Cancer, 2023

• DOI for Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
• Download full text (pdf) of Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Dijkstra, E. A.; Zwart, W. H.; Nilsson, P. J.; Putter, H. et al.

Part of ESMO Open, 2023

• DOI for The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats

Dahlgren, David; Rosenqvist, Evelina; Hellström, Per M.; Nygren, Peter et al.

Part of Basic & Clinical Pharmacology & Toxicology, p. 536-546, 2022

• DOI for Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats
• Download full text (pdf) of Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats

Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Bjersand, Kathrine; Blom, Kristin; Sundström Poromaa, Inger; Stålberg, Karin et al.

Part of International Journal of Oncology, 2022

• DOI for Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
• Download full text (pdf) of Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells

Karlsson, Henning; Fryknäs, Mårten; Senkowski, Wojciech; Larsson, Rolf et al.

Part of Oncology Letters, 2022

• DOI for Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
• Download full text (pdf) of Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Nyberg, Frida; Blom, Kristin; Selvin, Tove; Rudfeldt, Jakob et al.

Part of Scientific Reports, 2022

• DOI for Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
• Download full text (pdf) of Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Part of Scientific Reports, 2021

• DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
• Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial

Demmelmaier, Ingrid; Brooke, Hannah L.; Henriksson, Anna; Mazzoni, Anne-Sophie et al.

Part of Scandinavian Journal of Medicine and Science in Sports, p. 1144-1159, 2021

• DOI for Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial
• Download full text (pdf) of Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial

Fördelaktigt med genetisk analys före behandling med 5-fluorouracil: Utvärdering tyder på mindre biverkningar och kostnadsbesparing för sjukvården: [New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings]

Schultz, Alice; Kohnke, Hugo; Wadelius, Mia; Nygren, Peter

Part of Läkartidningen, 2021

Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial

Hauffman, Anna; Alfonsson, Sven; Bill-Axelson, Anna; Bergkvist, Leif et al.

Part of Psycho-Oncology, p. 2012-2018, 2020

• DOI for Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial
• Download full text (pdf) of Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial

Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.

Forslund, Marina; Ottenblad, Anna; Ginman, Claes; Johansson, Silvia et al.

Part of Supportive Care in Cancer, p. 3331-3342, 2020

• DOI for Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.
• Download full text (pdf) of Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.

Experiences of a nutrition intervention: A qualitative study within a randomised controlled trial in men undergoing radiotherapy for prostate cancer

Forslund, Marina; Nygren, Peter; Ottenblad, Anna; Johansson, Birgitta

Part of Nutrition & Dietetics, p. 223-230, 2020

• DOI for Experiences of a nutrition intervention: A qualitative study within a randomised controlled trial in men undergoing radiotherapy for prostate cancer

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy

Rendo, Verónica; Stoimenov, Ivaylo; Mateus, André; Sjöberg, Elin et al.

Part of Nature Communications, 2020

• DOI for Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
• Download full text (pdf) of Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020

• DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection

Månsson, Christopher; Nilsson, Anders; Nygren, Peter; Karlson, Britt-Marie

Part of Anticancer Research, p. 2771-2775, 2020

• DOI for Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter et al.

Part of Investigational new drugs, p. 684-692, 2019

• DOI for A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer

Glimelius, Bengt; Nygren, Peter

Part of Acta Oncologica, p. 395-397, 2019

• DOI for Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019

• DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer

Månsson, Christopher; Brahmstaedt, Richard; Nygren, Peter; Nilsson, Anders et al.

Part of Anticancer Research, p. 2509-2512, 2019

• DOI for Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer

Which exercise prescriptions optimize V̇O₂max during cancer treatment?: a systematic review and meta-analysis

Bjorke, Ann Christin Helgesen; Sweegers, Maike G.; Buffart, Laurien M.; Raastad, Truls et al.

Part of Scandinavian Journal of Medicine and Science in Sports, p. 1274-1287, 2019

• DOI for Which exercise prescriptions optimize V̇O₂max during cancer treatment?: a systematic review and meta-analysis

Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Daskalakis, Kosmas; Norlén, Olov; Karakatsanis, Andreas; Hellman, Per et al.

Part of Neuroendocrinology, p. 189-189, 2018

• DOI for Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors

Daskalakis, Kosmas; Norlén, Olov; Karakatsanis, Andreas; Hellman, Per et al.

Part of Endocrine-Related Cancer, p. 471-480, 2018

• DOI for Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius, Bengt; Melin, Beatrice; Enblad, Gunilla; Alafuzoff, Irina et al.

Part of Acta Oncologica, p. 187-194, 2018

• DOI for U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.
• Download full text (pdf) of U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Kashif, Muhammad; Andersson, Claes; Mansoori, Sharmineh; Larsson, Rolf et al.

Part of Oncotarget, p. 103952-103967, 2017

• DOI for Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
• Download full text (pdf) of Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Karlsson, Henning; Fryknäs, Mårten; Strese, Sara; Gullbo, Joachim et al.

Part of Oncotarget, p. 30217-30234, 2017

• DOI for Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
• Download full text (pdf) of Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Wickström, Malin; Nygren, Peter; Larsson, Rolf; Harmenberg, Johan et al.

Part of Oncotarget, p. 66641-66655, 2017

• DOI for Melflufen: a peptidase-potentiated alkylating agent in clinical trials
• Download full text (pdf) of Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Blom, Kristin; Nygren, Peter; Larsson, Rolf; Andersson, Claes R.

Part of SLAS TECHNOLOGY, p. 306-314, 2017

• DOI for Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Prognostic factors in patients with loco-regionally advanced gastric cancer

Hultman, Bo; Gunnarsson, Ulf; Nygren, Peter; Sundbom, Magnus et al.

Part of World Journal of Surgical Oncology, 2017

• DOI for Prognostic factors in patients with loco-regionally advanced gastric cancer
• Download full text (pdf) of Prognostic factors in patients with loco-regionally advanced gastric cancer

Targeting tumor cells based on Phosphodiesterase 3A expression

Nazir, Madiha; Senkowski, Wojciech; Nyberg, Frida; Blom, Kristin et al.

Part of Experimental Cell Research, p. 308-315, 2017

• DOI for Targeting tumor cells based on Phosphodiesterase 3A expression

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017

• DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE

Hauffman, Anna; Alfonsson, Sven; Mattson, Susanne; Forslund, Marina et al.

Part of Cancer Nursing, 2017

• DOI for The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE
• Download full text (pdf) of The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson, Anna; Chantzi, Efthymia; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Leukemia Research, p. 41-46, 2017

• DOI for Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
• Download full text (pdf) of Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials

Godskesen, Tove; Kihlbom, Ulrik; Nordin, Karin; Silen, Marit et al.

Part of European Journal of Cancer Care, p. 516-523, 2016

• DOI for Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Blom, Kristin; Nygren, Peter; Alvarsson, Jonathan; Larsson, Rolf et al.

Part of JALA, p. 178-187, 2016

• DOI for Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer

Padhan, Narendra; Nordling, Torbjorn E. M.; Sundström, Magnus; Åkerud, Peter et al.

Part of BMC Cancer, 2016

• DOI for High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer
• Download full text (pdf) of High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer

Iron chelators target both proliferating and quiescent cancer cells

Fryknäs, Mårten; Zhang, Xiaonan; Bremberg, Ulf; Senkowski, Wojciech et al.

Part of Scientific Reports, 2016

• DOI for Iron chelators target both proliferating and quiescent cancer cells
• Download full text (pdf) of Iron chelators target both proliferating and quiescent cancer cells

Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids

Senkowski, Wojciech; Jarvius, Malin; Rubin, Jenny; Lengqvist, Johan et al.

Part of CELL CHEMICAL BIOLOGY, p. 1428-1438, 2016

• DOI for Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids

Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

Stefansson, Måns; Nygren, Peter

Part of Acta Oncologica, p. 1227-1235, 2016

• DOI for Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy

Månsson, Christopher; Brahmstaedt, Richard; Nilsson, Anders; Nygren, Peter et al.

Part of European Journal of Surgical Oncology, p. 1401-1406, 2016

• DOI for Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy

Preclinical activity of melflufen (J1) in ovarian cancer

Carlier, Charlotte; Strese, Sara; Viktorsson, Kristina; Velander, Ebba et al.

Part of Oncotarget, p. 59322-59335, 2016

• DOI for Preclinical activity of melflufen (J1) in ovarian cancer

Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects

Eriksson, Anna; Gustafsson, Mats; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Haematologica, p. 367-368, 2016

Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells

Fakhoury, Isabelle; Saad, Walid; Bouhadir, Kamal; Nygren, Peter et al.

Part of Journal of nanoparticle research, 2016

• DOI for Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells

Always look at the bright side of drugs?

Nygren, Peter

Part of Acta Oncologica, p. 145-147, 2015

• DOI for Always look at the bright side of drugs?

Considerations on the Selection Process for Cytoreductive Surgery and Hyperthermic IntraPeritoneal Chemotherapy for Colorectal Carcinomatosis Reply

Cashin, Peter; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgery, 2015

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Eriksson, Anna; Österroos, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood Cancer Journal, 2015

• DOI for Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
• Download full text (pdf) of Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

Bjersand, Kathrine; Mahteme, Haile; Sundström Poromaa, Inger; Andreasson, Håkan et al.

Part of Annals of Surgical Oncology, 2015

• DOI for Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

• DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials

Godskesen, Tove; Hansson, Mats G.; Nygren, Peter; Nordin, Karin et al.

Part of European Journal of Cancer Care, p. 133-141, 2015

• DOI for Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Kashif, Muhammad; Andersson, Claes; Hassan, Sadia; Karlsson, Henning et al.

Part of Scientific Reports, 2015

• DOI for In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
• Download full text (pdf) of In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs

Aftab, Obaid; Fryknäs, Mårten; Hassan, Saadia; Nygren, Peter et al.

Part of Chemometrics and Intelligent Laboratory Systems, p. 24-32, 2015

• DOI for Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs

O-15-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases

Lubberink, Mark; Golla, Sanjeep S. V.; Jonasson, My; Rubin, Kristofer et al.

Part of Journal of Nuclear Medicine, p. 1144-1149, 2015

• DOI for O-15-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases

Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics

Senkowski, Wojciech; Zhang, Xiaonan; Nygren, Peter; Olofsson, Maria Hagg et al.

Part of Cancer Research, 2015

• DOI for Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics

Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

Senkowski, Wojciech; Zhang, Xiaonan; Olofsson, Maria Hagg; Isacson, Ruben et al.

Part of Molecular Cancer Therapeutics, p. 1504-1516, 2015

• DOI for Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Kashif, Muhammad; Andersson, Claes; Åberg, Magnus; Nygren, Peter et al.

Part of Molecular Cancer Therapeutics, p. 1964-1976, 2014

• DOI for A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Hultman, Bo; Mahteme, Haile; Sundbom, Magnus; Ljungman, Martin et al.

Part of Journal of Experimental & Clinical Cancer Research, 2014

• DOI for Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy
• Download full text (pdf) of Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome

von Heideman, Anne; Tholander, Bengt; Grundmark, Birgitta; Cajander, Stefan et al.

Part of Acta Oncologica, p. 242-250, 2014

• DOI for Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome

Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: Long-term results from a randomized controlled trial

Pettersson, Anna; Nygren, Peter; Persson, Christina; Berglund, Anders et al.

Part of Radiotherapy and Oncology, p. 240-247, 2014

• DOI for Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: Long-term results from a randomized controlled trial

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

• DOI for Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
• Download full text (pdf) of Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia

Eriksson, Anna; Osterros, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood, 2014

Safety and Preliminary Efficacy of Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Localized Pancreatic Cancer

Månsson, Christopher; Bergenfeldt, Magnus; Brahmstaedt, Richard; Karlson, Britt-Marie et al.

Part of Anticancer Research, p. 289-293, 2014

Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Cashin, Peter H; Mahteme, Haile; Graf, Wilhelm; Karlsson, Henning et al.

Part of BMC Cancer, p. 435, 2013

• DOI for Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
• Download full text (pdf) of Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Cashin, Peter H.; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgical Oncology, p. 4183-4189, 2013

• DOI for Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol

Mattsson, Susanne; Alfonsson, Sven; Carlsson, Maria; Nygren, Peter et al.

Part of BMC Cancer, p. 414, 2013

• DOI for Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol
• Download full text (pdf) of Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol

Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

Cashin, Peter H; Ehrsson, H; Wallin, I; Nygren, Peter et al.

Part of European Journal of Clinical Pharmacology, p. 533-540, 2013

• DOI for Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Godskesen, Tove; Nygren, Peter; Nordin, Karin; Hansson, Mats et al.

Part of Supportive Care in Cancer, p. 3137-3142, 2013

• DOI for Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

Hultman, Bo; Lind, Pehr; Glimelius, Bengt; Sundbom, Magnus et al.

Part of Acta Oncologica, p. 824-830, 2013

• DOI for Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Jarvius, Malin; Fryknäs, Mårten; D'Arcy, Padraig; Sun, Chao et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 117-123, 2013

• DOI for Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

Nygren, Peter; Fryknäs, Mårten; Anagel, Bengt; Larsson, Rolf

Part of Journal of Cancer Research and Clinical Oncology, p. 2133-2140, 2013

• DOI for Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
• Download full text (pdf) of Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Part of BMC Cancer, p. 374, 2013

• DOI for Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
• Download full text (pdf) of Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma

Hassan, Saadia Bashir; Gullbo, Joachim; Hu, Kefei; Berenjian, Saideh et al.

Part of Anticancer Research, p. 143-151, 2013

Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer

Hultman, Bo; Lundkvist, Jonas; Glimelius, Bengt; Nygren, Peter et al.

Part of Acta Oncologica, p. 112-121, 2012

• DOI for Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer

Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of European Journal of Surgical Oncology, p. 509-515, 2012

• DOI for Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study
• Download full text (pdf) of Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study

Evaluation of predictive markers for patients with advanced colorectal cancer

Byström, Per; Berglund, Åke; Nygren, Peter; Wernroth, Lisa et al.

Part of Acta Oncologica, p. 849-859, 2012

• DOI for Evaluation of predictive markers for patients with advanced colorectal cancer

Histopathological Classification of Pseudomyxoma Peritonei and the Prognostic Importance of PINCH Protein

Andreasson, Håkan; Wanders, Alkwin; Sun, Xiao-Feng; Willén, Roger et al.

Part of Anticancer Research, p. 1443-1448, 2012

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Haglund, Caroline; Åleskog, Anna; Nygren, Peter; Gullbo, Joachim et al.

Part of Cancer Chemotherapy and Pharmacology, p. 697-707, 2012

• DOI for In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Oncology, p. 647-652, 2012

• DOI for Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study
• Download full text (pdf) of Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study

Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system

Karlsson, Henning; Fryknäs, Mårten; Larsson, Rolf; Nygren, Peter

Part of Experimental Cell Research, p. 1577-1585, 2012

• DOI for Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system

Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei

Andréasson, Håkan; Graf, Wilhelm; Nygren, Peter; Glimelius, Bengt et al.

Part of European Journal of Surgical Oncology, p. 962-968, 2012

• DOI for Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei

Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis using Serum Tumour Markers – an Observational Cohort Study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgery, p. 1078-1083, 2012

• DOI for Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis using Serum Tumour Markers – an Observational Cohort Study

Pseudomyxoma Peritone: symptoms, treatment, prognosis and sensitivity to cytostatic drugs in vitro

Bjersand, Kathrine; Poromaa, Inger Sundström; Nygren, Peter; Mahteme, Haile

Part of Acta Obstetricia et Gynecologica Scandinavica, p. 71-71, 2012

• DOI for Pseudomyxoma Peritone: symptoms, treatment, prognosis and sensitivity to cytostatic drugs in vitro

Quality of life in peritoneal carcinomatosis after cytoreductive surgery and intraperitoneal chemotherapy

Hansson, Johan; Graf, Wilhelm; Nygren, Peter; Ring, Lena et al.

2012

Quantitative accuracy of parametric myocardial and tumour blood flow images based on HYPR-LR-filtered dynamic [O-15]water PET

Golla, Sandeep; Sörensen, Jens; Kero, Tanja; Harms, H. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2012

Response to comments on 'Cytoreductive surgery and intraperitoneal chemotherapy'

Cashin, Peter H.; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of European Journal of Surgical Oncology, p. 1012-1012, 2012

• DOI for Response to comments on 'Cytoreductive surgery and intraperitoneal chemotherapy'

The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines

Häggblad Sahlberg, Sara; Spiegelberg, Diana; Lennartsson, Johan; Nygren, Peter et al.

Part of International Journal of Oncology, p. 176-184, 2012

• DOI for The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines
• Download full text (pdf) of The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Suzuki, C; Blomqvist, L; Sundin, Anders; Jacobsson, H et al.

Part of Annals of Oncology, p. 948-954, 2012

• DOI for The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Aminopeptidase N (CD13) as a target for cancer chemotherapy

Wickström, Malin; Larsson, Rolf; Nygren, Peter; Gullbo, Joachim

Part of Cancer Science, p. 501-508, 2011

• DOI for Aminopeptidase N (CD13) as a target for cancer chemotherapy

Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: a retrospective study of in vitro drug sensitivity and survival

Cashin, Peter; Nygren, Peter; Hellman, Per; Granberg, Dan et al.

Part of Clinical Colorectal Cancer, p. 108-112, 2011

• DOI for Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: a retrospective study of in vitro drug sensitivity and survival

EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Wei, Q.; Shui, Y.; Zheng, S.; Wester, Kenneth et al.

Part of Oncology Reports, p. 3-11, 2011

• DOI for EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Novel activity of acriflavine against colorectal cancer tumor cells

Hassan, Saadia; Laryea, Daniel; Mahteme, Haile; Felth, Jenny et al.

Part of Cancer Science, p. 2206-2213, 2011

• DOI for Novel activity of acriflavine against colorectal cancer tumor cells

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Gullbo, Joachim; Fryknäs, Mårten; Rickardson, Linda; Darcy, Padraig et al.

Part of Biochemical Pharmacology, p. 139-147, 2011

• DOI for Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Berglund, Åke; Byström, Per; Johansson, Birgitta; Nygren, Peter et al.

Part of Medical Oncology, p. 65-72, 2010

• DOI for An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Byström, P.; Berglund, Åke; Nygren, Peter; Wernroth, Mona-Lisa et al.

Part of Oncology Reports, p. 1645-1652, 2010

• DOI for An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Laryea, Daniel; Gullbo, Joachim; Isaksson, Anders; Larsson, Rolf et al.

Part of Anti-Cancer Drugs, p. 33-42, 2010

• DOI for Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Hu, Kefei; Berenjian, Saideh; Larsson, Rolf; Gullbo, Joachim et al.

Part of International Journal of Nanomedicine, p. 51-62, 2010

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

von Heideman, Anne; Berglund, Åke; Larsson, Rolf; Nygren, Peter

Part of Cancer Chemotherapy and Pharmacology, p. 1165-1172, 2010

• DOI for Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data